Researchers have unveiled a groundbreaking strategy to combat drug-resistant prostate cancer by utilizing genetic mutations to boost immune responses. This novel approach, announced by an international team from the Weizmann Institute of Science in Israel, has been detailed in the journal Cancer Discovery.
A major hurdle in cancer treatment is treatment resistance, which occurs when tumors adapt to evade therapies like hormone treatments, chemotherapy, and targeted drugs. Initially, many cancers respond well to these treatments; however, over time, cancer cells can mutate, rendering these therapies ineffective.
Instead of focusing on blocking the cancer’s progression, the researchers zeroed in on the genetic mutations that surface when tumors resist treatment. They discovered that these mutations leave unique molecular markers or fingerprints on the cancer cells. To identify these fingerprints, the team developed an advanced computer tool called SpotNeoMet. This tool analyzes genetic data from tumors to detect prevalent resistance-related mutations across various patients.
These mutations lead to the production of small protein fragments known as neo-antigens, which are exclusive to cancer cells and absent in healthy cells-making them ideal targets for the immune system. The researchers aim to leverage these common neo-antigens to create new immunotherapies. These treatments would empower the immune system to recognize and attack cancer cells while sparing normal tissue. Their efforts were specifically directed at metastatic prostate cancer, a condition where many patients eventually stop responding to standard treatments.
Employing SpotNeoMet, the team identified three neo-antigens linked to drug resistance that were found in multiple patients. Lab experiments and animal studies showed that these neo-antigens triggered immune responses specifically targeting cancer cells.
This discovery marks a departure from highly personalized cancer treatments, which are often costly and time-consuming to develop for individual patients. Instead, this new method seeks to address resistance mutations in a broader patient population, potentially benefitting many individuals grappling with difficult-to-treat cancers.
The researchers believe that this approach could also be adapted for other cancers that develop treatment resistance. While further research and clinical trials are necessary before these treatments can be applied to patients, experts regard this finding as a significant step forward towards more effective and versatile cancer therapies.
Original Source: https://www.indianewsnetwork.com/en/new-strategy-targets-drug-resistant-prostate-cancer-using-genetics-20251231
Category:
Tags:
Publish Date: 2025-12-30 23:50:00
